Loading company
Transcode Therapeutics, Inc.
RNAZ · Nasdaq · ·
$1.67-2.9%Sep 29 close
- 1M
- -23.4%
- 6M
- -80.5%
- 1Y
- -84.5%
- 5Y
- -100.0%
RNAZ · Nasdaq · ·
$1.67-2.9%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$6.8M | -$4.3M | -57.84% |
| Profit per share | -$0.14 | -$0.00 | -69,350.00% |
| Free Cash Flow | -$3.1M | -$5.7M | +44.44% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Transcode Therapeutics, Inc. has no earnings call transcript available.
“We believe 2023 was extremely productive and pivotal for TransCode. We are proud to have advanced our lead therapeutic candidate, TTX-MC138, into the clinic as a first-in-class drug candidate against metastatic cancer. The year was highlighted by preliminary clinical results from our Phase 0 clinical trial with radiolabeled TTX-MC138,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Transcode Therapeutics, Inc.’s Item 2.02 8-K filed April 5, 2024; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.